Table 3.

Relative HRs (95% CI) compared to the group with UA level of 5–7 mg/dL for the association between mortality risks and uric acid levels among adults without diabetes and with diabetes.

Outcomes	Non-DM
	<5 (mg/dL) N = 11,545	5–7 (mg/dL) N = 11,895	7–9 (mg/dL) N = 3030	≥9 (mg/dL) N = 250
All-cause mortality (N = 1664)
un-weighted	1.02 (0.8–1.18)	1.0 (reference)	1.26 (1.06–1.49) *	2.44 (1.63–3.66) *
weighted a	1.03 (0.87–1.22)	1.0 (reference)	1.43 (1.15–1.79) *	2.41 (1.42–4.08) *
CVD mortality (N = 378)
un-weighted	1.06 (0.78–1.44)	1.0 (reference)	1.37 (0.96–1.95)	2.97 (1.37–6.45) *
weighted a	1.22 (0.82-1.82)	1.0 (reference)	1.76 (1.22–2.56) *	5.06 (1.69–15.15) *
Cancer death (N = 436)
un-weighted	1.06 (0.82-1.36)	1.0 (reference)	1.09 (0.79–1.49)	2.39 (1.17–4.90) *
weighted a	1.04 (0.75-1.45)	1.0 (reference)	1.25 (0.90–1.73)	1.43 (0.64–3.21)
CVD or Cancer death (N = 814)
un-weighted	1.06 (0.87-1.29)	1.0 (reference)	1.19 (0.94–1.51)	2.63 (1.56–4.45) *
weighted a	1.10 (0.84-1.43)	1.0 (reference)	1.42 (1.08–1.87) *	2.60 (1.21–5.58) *
	DM
	N = 973	N = 1141	N = 345	N = 47
All-cause mortality (N = 405)
un-weighted	1.33 (1.01–1.75) *	1.0 (reference)	1.69 (1.22–2.34) *	1.41 (0.65–3.08)
weighted a	1.66 (1.14–2.41) *	1.0 (reference)	2.17 (1.49–3.17) *	2.10 (0.87–5.06)
CVD mortality (N = 117)
un-weighted	0.71 (0.41–1.24)	1.0 (reference)	1.75 (0.95–3.23)	1.91 (0.45–8.11)
weighted a	0.91 (0.38–2.18)	1.0 (reference)	2.53 (1.18–5.41) *	0.89 (0.18–4.50)
Cancer death (N = 84)
un-weighted	1.82 (1.01–3.26) *	1.0 (reference)	1.81 (0.85–3.85)	2.60 (0.59–11.40)
weighted a	2.13 (0.84–5.42)	1.0 (reference)	2.13 (0.88–5.12)	4.51 (0.89-22.78)
CVD or Cancer death (N = 201)
un-weighted	1.10 (0.74–1.63)	1.0 (reference)	1.75 (1.09–2.81)	2.15 (0.77–6.04)
weighted a	1.36 (0.77–2.43)	1.0 (reference)	2.30 (1.34–3.96) *	2.60 (0.69–9.80)

^a Data are weighted estimates. Adjusted for BMI, sex, age, race, HDL-Cholesterol, current smoking status, SBP and creatinine. * p < 0.05.